Literature DB >> 24587872

Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.

Leila Green1, Funda Meric-Bernstam1.   

Abstract

BRCA1 and BRCA2 mutation carriers with breast cancer have a high risk of ipsilateral breast cancer tumor recurrence (IBTR) and a high lifetime risk of contralateral breast cancer (CBC). The IBTR risk is significantly higher in women who elect breast conservation. Oophorectomy has a protective effect for both ipsilateral breast tumor recurrence and CBC. Patients with younger age of breast cancer onset have a significantly greater risk of CBC. Given the higher risk of IBTR and CBC, when indicated, patients with breast cancer should undergo genetic counseling early in their treatment course to assist them in their surgical decision-making. Knowledge of expected outcomes for BRCA1/2 mutation carriers following breast cancer treatment can help appropriately council patients and personalize cancer therapy.

Entities:  

Keywords:  BRCA1; BRCA2; Contralateral Breast Cancer; prophylactic mastectomy

Year:  2011        PMID: 24587872      PMCID: PMC3938200          DOI: 10.1007/s12609-011-0047-3

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN: 1943-4588


  19 in total

1.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.

Authors:  Lori J Pierce; Albert M Levin; Timothy R Rebbeck; Merav A Ben-David; Eitan Friedman; Lawrence J Solin; Eleanor E Harris; David K Gaffney; Bruce G Haffty; Laura A Dawson; Steven A Narod; Ivo A Olivotto; Andrea Eisen; Timothy J Whelan; Olufunmilayo I Olopade; Claudine Isaacs; Sofia D Merajver; Julia S Wong; Judy E Garber; Barbara L Weber
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.

Authors:  Min Yi; Kelly K Hunt; Banu K Arun; Isabelle Bedrosian; Angelica Gutierrez Barrera; Kim-Anh Do; Henry M Kuerer; Gildy V Babiera; Elizabeth A Mittendorf; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-20

3.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.

Authors:  Jacek Gronwald; Nadine Tung; William D Foulkes; Kenneth Offit; Ruth Gershoni; Mary Daly; Charmaine Kim-Sing; Hakan Olsson; Peter Ainsworth; Andrea Eisen; Howard Saal; Eitan Friedman; Olufunmilayo Olopade; Michael Osborne; Jeffrey Weitzel; Henry Lynch; Parviz Ghadirian; Jan Lubinski; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

5.  Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.

Authors:  Jane C Figueiredo; Jennifer D Brooks; David V Conti; Jenny N Poynter; Sharon N Teraoka; Kathleen E Malone; Leslie Bernstein; Won D Lee; David J Duggan; Ashley Siniard; Patrick Concannon; Marinela Capanu; Charles F Lynch; Jørgen H Olsen; Robert W Haile; Jonine L Bernstein
Journal:  Breast Cancer Res Treat       Date:  2010-12-15       Impact factor: 4.872

6.  Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Authors:  D Schrag; K M Kuntz; J E Garber; J C Weeks
Journal:  JAMA       Date:  2000-02-02       Impact factor: 56.272

7.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

Authors:  Tari A King; Rita Sakr; Sujata Patil; Inga Gurevich; Michelle Stempel; Michelle Sampson; Monica Morrow
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

8.  Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.

Authors:  Lori J Pierce; Kelly-Anne Phillips; Kent A Griffith; Saundra Buys; David K Gaffney; Meena S Moran; Bruce G Haffty; Merav Ben-David; Bella Kaufman; Judy E Garber; Sofia D Merajver; Judith Balmaña; Amichay Meirovitz; Susan M Domchek
Journal:  Breast Cancer Res Treat       Date:  2010-04-22       Impact factor: 4.872

9.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Stephanie Jarosek; Elizabeth B Habermann; Amanda Arrington; Anasooya Abraham; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

10.  Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.

Authors:  Xiang Gao; Susan G Fisher; Bahman Emami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

View more
  1 in total

1.  Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.

Authors:  Brittany L Murphy; Min Yi; Banu K Arun; Angelica M Gutierrez Barrera; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.